摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-{1-(R)-[4-(3,4-Dichlorobenzyl)piperidin-1-ylmethyl]-2-methylpropyl}-3-(3,4,5-trimethoxyphenyl)urea | 270251-12-2

中文名称
——
中文别名
——
英文名称
1-{1-(R)-[4-(3,4-Dichlorobenzyl)piperidin-1-ylmethyl]-2-methylpropyl}-3-(3,4,5-trimethoxyphenyl)urea
英文别名
1-[(2R)-1-[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]-3-methylbutan-2-yl]-3-(3,4,5-trimethoxyphenyl)urea
1-{1-(R)-[4-(3,4-Dichlorobenzyl)piperidin-1-ylmethyl]-2-methylpropyl}-3-(3,4,5-trimethoxyphenyl)urea化学式
CAS
270251-12-2
化学式
C27H37Cl2N3O4
mdl
——
分子量
538.514
InChiKey
FQHUEFRHSWYBQS-QHCPKHFHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.2
  • 重原子数:
    36
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    72.1
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
    申请人:Laboratorios Almirall, S.A.
    公开号:EP2108641A1
    公开(公告)日:2009-10-14
    This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.
    这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂;其制备方法;包含它们的药物组合物;以及它们在治疗中的应用。
  • New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
    申请人:Almirall, S.A.
    公开号:EP2322176A1
    公开(公告)日:2011-05-18
    This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to pharmaceutical compositions comprising them, and to their use in therapy.
    这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂,以及包含它们的药物组合物,以及它们在治疗中的应用。
  • [EN] NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE 7-PHÉNYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE
    申请人:ALMIRALL SA
    公开号:WO2011057757A1
    公开(公告)日:2011-05-19
    This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to processes for their preparation, to pharmaceutical compositions comprising them, and to their use in therapy.
    这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂,涉及它们的制备方法,包括它们的药物组合物,以及它们在治疗中的应用。
  • New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
    申请人:Laboratorios Almirall, S.A.
    公开号:EP2113503A1
    公开(公告)日:2009-11-04
    This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.
    这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂;其制备方法;包含它们的药物组合物;以及它们在治疗中的应用。
  • Cyclic amine derivatives-CCR-3 receptor antagonists
    申请人:Syntex (U.S.A.) LLC
    公开号:US06339087B1
    公开(公告)日:2002-01-15
    This invention relates to certain cyclic amine derivatives of Formula (I) that are CCR-3 receptor antagonist, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    这项发明涉及某些符合以下式(I)的环胺衍生物,它们是CCR-3受体拮抗剂,包含它们的药物组合物,以及它们的使用方法和制备这些化合物的方法。
查看更多